Literature DB >> 24544

Antagonism by mianserin and classical alpha-adrenoceptor blocking drugs of some cardiovascular and behavioral effects of clonidine.

R D Robson, M J Antonaccio, J K Saelens, J Liebman.   

Abstract

Antagonism of pressor responses to sympathetic outflow stimulation and alpha-adrenoceptor agonists in pithed spontaneously hypertensive rats was used to estimate postsynaptic alpha-adrenoceptor blocking activity of mianserin, phentolamine, phenoxybenzamine, piperoxan and yohimbine. Estimation of presynaptic alpha-adrenoceptor blocking activity of these drugs was obtained by studying their ability to antagonize clonidine-induced suppression of positive chronotropic responses to sympathetic outflow stimulation. In this manner, evidence was obtained that mianserin causes selective presynaptic alpha-adrenoceptor blockade. Mianserin, piperoxan and yohimbine antagonized clonidine-induced avoidance blockade or hypotension in spontaneously hypertensive rats, but methysergide, phenoxybenzamine and phentolamine were ineffective. These results suggest that mianserin may antagonize the central effects of clonidine by blockade of noradrenergic presynaptic or autoreceptors and possibly explain the antidepressant effect of mianserin as due to indirect activation of central noradrenergic neurons.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24544     DOI: 10.1016/0014-2999(78)90124-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Effects of mianserin on noradrenaline uptake, cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors in rats [proceedings].

Authors:  I Cavero; R Gomeni; F Lefèvre-Borg; A G Roach
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

2.  Involvement of presynaptic alpha-adrenoceptors in the cardiovascular and sedative effects of FLA-136.

Authors:  P B Timmermans; E Lam; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

3.  Discriminative stimulus effects of the alpha 2-adrenoceptor antagonist idazoxan.

Authors:  D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Depression of exploratory activity by clonidine in rats as a model for the detection of relative pre- and postsynaptic central noradrenergic receptor selectivity of alpha-adrenolytic drugs.

Authors:  A Delini-Stula; P Baumann; O Büch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-06       Impact factor: 3.000

5.  Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats.

Authors:  I Cavero; F Lefèvre-Borg; A G Roach
Journal:  Br J Pharmacol       Date:  1981-09       Impact factor: 8.739

6.  Differences in presynaptic alpha-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)- and (-)mianserin.

Authors:  H Schoemaker; H H Berendsen; H J Stevens; V J Nickolson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Anxiolytics antagonize yohimbine's discriminative stimulus properties.

Authors:  R G Browne
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Differential reversal of various dopamine antagonists by anticholinergics in Sidman avoidance: possible relationship to adrenergic blockade.

Authors:  J M Liebman; R Neale; L Noreika; A Braunwalder
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  A study of the effects of clonidine on the EEG in rats treated with single and multiple doses of antidepressants.

Authors:  W Kostowski; W Dyr; B Zacharski
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 10.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.